Panel Discussion: Ensuring Lasting Therapeutic Responses from Allogeneic Therapy – Is Redosing the Way to Go?
Time: 8:30 am
day: Conference Day Two
Details:
Examine the role of redosing in sustaining therapeutic efficacy and preventing disease relapse in patients receiving
allogeneic therapies
- How do we determine if multiple doses are needed and if so, how do we determine how many?
- Is it better to use a one and done model or plan for multiple doses?
- Analyze the impact of treatment schedules and regiments such as lymphodepletion on patient outcomes when scheduling multiple doses
